Equilis Te


Adjuvanted vaccine against tetanus

This medicine is authorised for use in the European Union.


Equilis Te is a veterinary vaccine used to protect horses from six months of age against tetanus to prevent mortality. Tetanus is an acute, often fatal disease caused by a neurotoxin produced by the bacterium Clostridium tetani. The disease, which usually originates from contaminated wounds, is characterised by overall rigidity (stiffness) and convulsive spasms of the muscles. Horses belong to the most susceptible species to tetanus. It contains the active substance tetanus toxoid.

This EPAR was last updated on 15/02/2021

Authorisation details

Product details
Equilis Te
Agency product number
Active substance
tetanus toxoid
International non-proprietary name (INN) or common name
Adjuvanted vaccine against tetanus
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Intervet International BV
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Intervet International B.V.
Wim de Körverstraat 35
5831 AN Boxmeer
The Netherlands

Product information

20/05/2019 Equilis Te - EMEA/V/C/000093 - IG/1104

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Immunologicals for equidae

Therapeutic indication

Active immunisation of horses from 6 months of age against tetanus to prevent mortality.

Onset of immunity: 2 weeks after the primary vaccination course

Duration of immunity: 17 months after the primary vaccination course, 24 months after the first revaccination

Assessment history

How useful was this page?

Add your rating